Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.8441 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
Patient Access Initiative Addresses €1 Billion Annual Market in Germany 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Year-End 2022 Corporate Review
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Third Quarter 2022 Update
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
Via AB Newswire
Mainz Biomed Best-In-Class Colorectal Cancer Screening Diagnostics Expand International Presence, Targets Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
Mainz Biomed Best-In-Class Cancer Screening Diagnostics Tap Into Billion Dollar Market Opportunities ($MYNZ)
Via AB Newswire
Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
Via AB Newswire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed (NASDAQ:MYNZ) could storm Wall Street with its molecular genetic diagnostic solutions for life-threatening conditions
Via AB Newswire
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ)
Via AB Newswire
Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
Via AB Newswire
Topics Bonds Economy Stocks
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the... 
Via FinancialNewsMedia
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force... 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.